Tuesday, June 18, 2024
HomeVideosTriple Negative Breast Cancer Cell Lines

Triple Negative Breast Cancer Cell Lines

Revitalizing The Azt Through Of The Selenium: An Approach In Human Triple Negative Breast Cancer Cell Line

Understanding the evolution of triple-negative breast cancer cells
  • 1Programa de Pós-Graduação em Biotecnologia, Grupo de Pesquisa em Oncologia Celular e Molecular, Biotecnologia/Centro de Desenvolvimento Tecnológico, Universidade Federal de Pelotas, Pelotas, Brazil
  • 2Departamento de Fisiologia e Farmacologia, Universidade Federal de Pelotas, Pelotas, Brazil
  • 3LabSelen-NanoBio – Universidade de Federal de Santa Maria, Santa Maria, Brazil

What Is The Treatment For Triple

Chemotherapy.Chemotherapy is almost always called for, Sun says. Chemo can downstage tumors . While Sun says the chemotherapy for triple-negative breast cancer can be intense, she adds that regimen can be tailored to the individual and adjusted for older or frailer patients.

In those cases where we get complete response, we know we gave you the right medicine and your prognosis is good, Sun says.

Surgery can remove more of the tumor. Surgery for triple-negative breast cancer does not always have to be a mastectomy, Sun says. Effective chemotherapy done first opens up the possibility of less-invasive surgical options that are less of an ordeal for the patient. If the tumor is small enough after chemo, outpatient procedures or a lumpectomy may be possible.

Surgical samples of the cancerous tissues taken from surgery can provide more information on the cancer and how it is behaving so chemotherapy can be tailored accordingly.

Radiation therapy involves the use beams of radiation to destroy cancer cells, using various techniques to prevent damage to healthy surrounding tissue.

Medical treatments are being tested on triple-negative breast tumors in clinical trials.

Immunotherapy and PARP inhibitors are very exciting and theres lots of research going on, including here at Johns Hopkins, Sun says.

Hcc70 Response To Radiation

To determine the benefit of paclitaxel in combination with focal radiation, we further employed HCC70 tumor bearing mice to investigate both fractionated and hypofractionated radiation treatment plans.

The HCC70 tumor model was sensitive to radiation, and we found that hypofractionated radiation resulted in a slightly improved anti-tumor response with a slightly increased toxicity profile, based on body weight loss . However, neither radiation treatment resulted in tumor free survivors, only prolonged tumor stasis based on caliper measurements .

Table 1: Endpoint Analysis Following Treatment with Paclitaxel and Focal Radiation

You May Like: Breast Cancer In Males Symptoms

List Of Breast Cancer Cell Lines

Scientists study the behaviour of isolated cells grown in the laboratory for insights into how cells function in the body in health and disease. Experiments using cell culture are used for developing new diagnostic tests and new treatments for diseases.This is a list of major breast cancer cell lines that are primarily used in breast cancer research.

Role Of P63 And P73 In Sensitizing Basal

Biomarker could help guide cancer therapy, avoid drug resistance

Studies have suggested that 0% to 30% of invasive ductal breast carcinomas express Np63 protein . p73 can induce apoptosis by p53-independent mechanisms, making it particularly important for therapeutics in basal-like breast carcinomas, which are most often null or mutant for p53. We found that p63 is significantly overexpressed in TNBC cell lines by analyzing gene expression data from a study published by Neve and colleagues . Because p63 can act as an oncogene , the correlation between p63 expression and PJ34- and gemcitabine-mediated cell death becomes even more important.

Also Check: Ovary Removal After Breast Cancer

Where Do These Numbers Come From

The American Cancer Society relies on information from the Surveillance, Epidemiology, and End Results Program database, maintained by the National Cancer Institute , to provide survival statistics for different types of cancer.

The SEER database tracks 5-year relative survival rates for breast cancer in the United States, based on how far the cancer has spread. The SEER database, however, does not group cancers by AJCC TNM stages . Instead, it groups cancers into localized, regional, and distant stages:

  • Localized: There is no sign that the cancer has spread outside of the breast.
  • Regional: The cancer has spread outside the breast to nearby structures or lymph nodes.
  • Distant: The cancer has spread to distant parts of the body such as the lungs, liver, or bones.

Cell Lines And Reagents

All cell lines were used within 6 months of purchase. MDAMB468, hs578t, MCF7, BT549, and BT474 cell lines were obtained from the American Type Culture Collection and maintained in DMEM with 10% fetal bovine serum . T47D and HCC1806 cells were maintained in RPMI 1640 with 10% FBS. ATCC provides molecular authentication in support of their collection through their genomics, immunology, and proteomic cores, as described, using DNA barcoding and species identification, quantitative gene expression, and transcriptome analyses . SUM149PT cells were obtained from Asterand Plc, where they were authenticated through gene expression data through the use of Affymetrix GeneChips and biomolecular markers, such as ER and HER2 status. They were maintained in Ham’s F-12 medium with 10% FBS. HCC1806 cells were transfected with the shRNAmir retroviral vector in pSM2 against nonspecific silencing control, PARP1 or PARP2 . Stable clones were maintained with 1 g/mL puromycin and confirmed by Western blotting. The PARP inhibitor PJ34 was purchased from EMD Biosciences. Methylene blue, MTT, and cisplatin were purchased from Sigma Chemicals. Gemcitabine was a gift from Eli Lilly Pharmaceuticals.

Read Also: Can 14 Year Olds Get Breast Cancer

Safety Data Sheet Download

Open the Safety Data Sheet for this product to download.

If a requested product is not a hazardous chemical, or does not contain any hazardous chemicals, a SDS is not required and therefore will not be provided.

Please check the Product Sheet and Safety Data Sheet Landing page for more information.

ATCC determines the biosafety level of a material based on our risk assessment as guided by the current edition of Biosafety in Microbiological and Biomedical Laboratories , U.S. Department of Health and Human Services. It is your responsibility to understand the hazards associated with the material per your organizations policies and procedures as well as any other applicable regulations as enforced by your local or national agencies.

ATCC highly recommends that appropriate personal protective equipment is always used when handling vials. For cultures that require storage in liquid nitrogen, it is important to note that some vials may leak when submersed in liquid nitrogen and will slowly fill with liquid nitrogen. Upon thawing, the conversion of the liquid nitrogen back to its gas phase may result in the vial exploding or blowing off its cap with dangerous force creating flying debris. Unless necessary, ATCC recommends that these cultures be stored in the vapor phase of liquid nitrogen rather than submersed in liquid nitrogen.

What Does Triple Negative Mean In Terms Of Breast Cancer

How Is Triple-Negative Breast Cancer Treated?

Normal breast cells have receptors that respond to hormones such as estrogen and progesterone, which allows them to grow and regress in response to the hormone level. Hormone receptors may or may not be present in breast cancer. About two-thirds of breast cancers are positive and contain these receptors like normal breast cells do. These are less aggressive cancers that are less likely to need chemo and are often treated with hormone therapy and surgery. Radiation may or may not be needed.

HER2/neu , is a protein molecule that has a role in cell proliferation in normal cells. In some breast cancers, this protein is overly produced or positive. For HER2-positive tumors, there a specific medication that targets this protein.

Triple-negative breast cancers are not positive for estrogen receptors, progesterone receptors or HER2 protein. Since these targets are absent in triple-negative breast cancer, chemotherapy is needed, Sun says. Triple-negative breast cancer is often very sensitive to chemotherapy, which, despite the side effects, is an effective treatment that can save lives. Because this is an aggressive cancer, treatment is aggressive also. But there are several ways we can address it.

Recommended Reading: Stage 3 Metastatic Breast Cancer

Inhibits Viability Of Tnbc Cd44high/cd24low Breast Cancer Stem Cells

We next evaluated the effect of 108600 treatment on growth of an expanded panel of breast cancer cell lines, as well as six normal and nontransformed cells. The kinases targeted by 108600 are robustly expressed in most TNBC cell lines, with relatively lower expression in normal cells . 108600 potently inhibited the viability of all triple negative and other breast tumor cell lines with little or no toxicity against normal cells, including normal mammary epithelial cell lines derived from two different donors . The growth suppression of TNBC cells observed with 108600 treatment was phenocopied by simultaneous transfection of cells with three siRNA pools targeting CK2, DYRK1A, and TNIK . Transfection of MDA-MB-231 or Hs578T cells with siRNA pools individually targeting CK2, DYRK1A, or TNIK had little or moderate effects on growth, supporting the need for simultaneous multi-kinase targeting . Individual siRNAs targeting CK2, DYRK1A, or TNIK suppressed phosphorylation of their respective, reported substrates, thereby phenocopying the effects of 108600 treatment and further validating that these kinases are indeed targeted by 108600 .

The Importance Of Using Patients Tumors As Models For Preclincial Research

Considerable observations obtained from patients tumors cannot be mimicked by using breast cancer cell lines. Acerbi et al recently demonstrated that crosstalk between the extracellular matrix and inflammation promotes invasion in 20 breast cancer patient biopsies . Increased amounts of collagen were deposited within invasive breast cancer. Furthermore, the collagen was thicker, underwent a linear reorganization in the stroma of the invasive lesions, and was associated with increased mechano-signalling and increased stromal stiffness. The invasive edge of the tumors possessed the greatest stromal stiffness illustrating regional stromal heterogeneity. This stiffness at the tumor edge was caused by accumulating activated macrophages and increased TGF- activity, suggesting a crosstalk between macrophage accumulation, stromal stiffness and tumor invasion. TNBC patient tumors possessed the greatest stromal stiffness, macrophage accumulation, and TGF- activation at the tumor front compared to the other breast cancer subtypes. Additionally, TNBC exhibited increased YAP signalling that correlated with stromal stiffness, tumor aggression and invasion. YAP is a mechanically activated signaling pathway that is associated with cancer stem cells and poor patient prognosis . This study highlights the multifaceted interplay between tumor cells, the extra cellular matrix and the immune system, which cannot be modeled by the cultured breast cancer cell lines and their xenografts.

You May Like: Breast Cancer Treatment With Implants

Analysis Of Gene Expression

The expression levels of pro and anti-apoptotic genes in MCF-7 and MDA-MB 231 cells were evaluated by qRT-PCR . Figure 6A shows the levels of expression in MCF-7 line. Figure 6B shows the levels of expression in MDA-MB 231 cell line, in which we observed significant difference compared to control for caspase 3 and 8 genes after treatment with derivative 1072 . No difference was observed for the other genes evaluated .

Assessment Of Cell Viability By Live/dead Assay

Pathology Outlines

The LIVE/DEAD cell viability assay was conducted following the manufacturer’s instructions. Cells were cultured and incubated with the AZT derivatives as described above. Live cells were analyzed by green fluorescent light emission , resulted from calcein uptake. Permeable membrane of dead cells allows diffusion of ethidium bromide homodimer and its binding to DNA, which was detected by the red fluorescent signal . The results were analyzed in a Olympus IX71 fluorescence microscope by multicolor imaging using a digital camera . The recorded images were analyzed using CellF software . The data were expressed as the mean ± SEM of percentage of dead cell, based 3 different fields of view, with 100 cells per field.

Recommended Reading: Can Breast Cancer Stop Your Period

Inhibits The Growth Of Tnbc In Vivo

Before determining the efficacy of 108600 against TNBC growth in vivo, we first established a dosing regimen based on toxicity data and suppression of 108600 target kinase activities. We performed a pilot study whereby CTG1883 tumor-bearing NSG mice were treated with vehicle or 108600 for a 5-day period. Whole-cell extracts derived from the tumors were subjected to western blot analysis using antibodies directed against pAKT1 Ser129, pCYCLIN D1 Thr286, and C-MYC as readouts for CK2, DYRK1A, and TNIK kinase inhibition, respectively. . Fig. and supplementary fig show that the levels of pAKT1 Ser129, pCYCLIN D1 Thr286 and C-MYC were decreased in the tumors isolated from 108600-treated animals, suggesting that loss of AKT phosphorylation and/or that of CYCLIN D1 as well as MYC expression might serve as relevant biomarkers in vivo. Based on the results of this experiment, administration of 108600 on a q2D schedule at a dose of 100mg/kg was chosen for subsequent studies in tumor-bearing mouse models.

Fig. 6: 108600 suppresses growth of TNBC cell line and PDX tumor grafts.

Similar Articles Being Viewed By Others

Carousel with three slides shown at a time. Use the Previous and Next buttons to navigate three slides at a time, or the slide dot buttons at the end to jump three slides at a time.

11 January 2019

Hongyu Zhou, Chunlei Yu, Yan Li

18 January 2019

Ling Wu, Fanyan Meng, Guojun Wu

15 February 2021

Konstantinos V. Floros, Sheeba Jacob, Anthony C. Faber

25 February 2022

Alice Turdo, Miriam Gaggianesi, Matilde Todaro

volume 12, Article number: 4671

This article has been

Also Check: What Are The Ways To Prevent Breast Cancer

What Is The Prognosis For Triple

A good treatment result depends on several factors. Chemotherapy is what can really make a difference in the outcome. The size of the invasive part of the tumor, and the number of involved lymph nodes can also greatly influence your prognosis, Sun says, but adds that if the cancer has spread , the prognosis is less certain.

There is hope, even with this serious diagnosis, and staying optimistic is essential. It can be stressful and scary to go through chemo, but positive thinking can make a difference. You have to believe that its doing you good, and for most people, it does.

What You Need To Know

Brain metastases developed from HER2 postive and triple negative breast cancer
  • Triple-negative breast cancer accounts for about 10% to 20% of all breast cancer cases.
  • Every cancer diagnosis is unique, but in general, triple-negative breast cancer is a more aggressive type of tumor with a faster growth rate, higher risk of metastasis and recurrence risk. Therefore, it often requires chemotherapy as part of the treatment.
  • Surgery is also an important part of treatment, but if a tumor is small and localized, mastectomy may not be necessary. Chemotherapy can shrink triple-negative breast tumors, and patients can become candidates for less-extensive surgery.
  • Triple-negative cancers are more common in patients with hereditary genetic mutations, and genetic counseling and testing should be considered.

Don’t Miss: What Does Breast Cancer Look Like Inside The Body

Modelling Drug Responses And Evolutionary Dynamics Using Triple Negative Breast Cancer Patient

  • For correspondence:

Survival Rates For Triple

Triple-negative breast cancer is considered an aggressive cancer because it grows quickly, is more likely to have spread at the time its found, and is more likely to come back after treatment than other types of breast cancer. The outlook is generally not as good as it is for other types of breast cancer.

Survival rates can give you an idea of what percentage of people with the same type and stage of cancer are still alive a certain amount of time after they were diagnosed. They cant tell you how long you will live, but they may help give you a better understanding of how likely it is that your treatment will be successful.

Keep in mind that survival rates are estimates and are often based on previous outcomes of large numbers of people who had a specific cancer, but they cant predict what will happen in any particular persons case. These statistics can be confusing and may lead you to have more questions. Talk with your doctor about how these numbers may apply to you, as they are familiar with your situation.

Don’t Miss: How To Tell If You Have Breast Cancer

Hcc: A Model Of Triple Negative Breast Cancer

Maryland Franklin, PhD | Vice President, Scientific DevelopmentDate: August 2018

Triple negative breast cancer , accounting for 15-20% of all breast cancers, lacks estrogen receptors, progesterone receptors, and amplification or overexpression of Her-2. As such, these tumors are not responsive to hormonal or anti-Her2 therapies, and are usually treated with combinations of surgery, radiation, and chemotherapy. Although many triple negative tumors respond well to chemotherapy, patients generally have poorer prognosis, higher relapse rates with aggressive tumor growth, and high metastatic potential. More than 300 clinical trials are currently ongoing in TNBC evaluating various single agent and combination approaches with chemotherapy, targeted therapy, immunotherapy, and radiation therapy. Clinically, radiation therapy has been associated with decreased risk of locoregional recurrence and some instances of improved overall survival when compared to patients that did not receive radiation therapy.1, 2

Preclinically there are few options to test effects of clinically relevant radiation therapy approaches. Labcorp has a Small Animal Radiation Research Platform in house and can provide a solution to this currently unmet preclinical need.


Popular Articles